Drug Trial Radar · NCT06956235
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
149
Actual
Start
Jun 9, 2025
Primary completion
Apr 2, 2026
Study completion Jun 6, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Conditions
- Hidradenitis Suppurativa
Interventions
TulisokibartDrug
Solution in autoinjector for subcutaneous (SC) injection
PlaceboDrug
Solution in autoinjector for SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 50 at Week 16Time frame: Week 16
Locations
68 sites in 15 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center ( Site 0012)
Birmingham, Alabama
Medical Dermatology Specialists ( Site 0027)
Phoenix, Arizona
Northwest Arkansas Clinical Trials Center, PLLC ( Site 0049)
Rogers, Arkansas
Northridge Clinical Trials ( Site 0004)
Northridge, California
Integrative Skin Science and Research ( Site 0015)
Sacramento, California
Olympian Clinical Research ( Site 0010)
Tampa, Florida
Skin Care Physicians of Georgia ( Site 0033)
Macon, Georgia
Dawes Fretzin Clinical Research Group, LLC ( Site 0025)
Indianapolis, Indiana
Beth Israel Deaconess Medical Center ( Site 0044)
Boston, Massachusetts
Revival Research Institute, LLC ( Site 0005)
Troy, Michigan
Mount Sinai Doctors - East 85th Street ( Site 0050)
New York, New York
DJL Clinical Research, PLLC ( Site 0021)
Charlotte, North Carolina
University Hospitals Cleveland Medical Center ( Site 0046)
Cleveland, Ohio
Wright State Physicians Health Center ( Site 0041)
Fairborn, Ohio
Palmetto Clinical Trial Services, LLC ( Site 0023)
Anderson, South Carolina
Arlington Center for Dermatology ( Site 0045)
Arlington, Texas
Texas Dermatology Research Center ( Site 0019)
Dallas, Texas
Reveal Research Institute ( Site 0018)
Frisco, Texas
Progressive Clinical Research ( Site 0020)
San Antonio, Texas
CIPREC ( Site 0202)
CABA, Argentina
Hospital Italiano de Buenos Aires ( Site 0205)
CABA, Argentina
Psoriahue ( Site 0203)
CABA, Argentina
Derma Internacional SA ( Site 0206)
CABA, Argentina
Liverpool Hospital ( Site 1403)
Liverpool, New South Wales, Australia
The Alfred Hospital ( Site 1401)
Melbourne, Victoria, Australia
Fremantle Dermatology ( Site 1402)
Fremantle, Western Australia, Australia
Wiseman Dermatology Research Inc. ( Site 0107)
Winnipeg, Manitoba, Canada
Brunswick Dermatology Center ( Site 0101)
Frederiction, New Brunswick, Canada
Lynderm Research Inc. ( Site 0104)
Markham, Ontario, Canada
SKiN Centre for Dermatology ( Site 0103)
Peterborough, Ontario, Canada
York Dermatology Clinic & Research Centre ( Site 0106)
Richmond Hill, Ontario, Canada
Centro Skin Med Limitada ( Site 0305)
Santiago, Region M. de Santiago, Chile
Clinica Dermacross ( Site 0301)
Santiago, Region M. de Santiago, Chile
Centro Internacional de Estudios Clinicos (CIEC) ( Site 0302)
Santiago, Region M. de Santiago, Chile
Dermatology Hospital of Southern Medical University ( Site 1504)
Guangzhou, Guangdong, China
The Second Xiangya Hospital of Central South University ( Site 1505)
Changsha, Hunan, China
The First Hospital of Jilin University ( Site 1502)
Changchun, Jilin, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine ( Site 1515)
Shanghai, Shanghai Municipality, China
Huashan Hospital of Fudan University ( Site 1506)
Shanghai, Shanghai Municipality, China
PEOPLE'S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION ( Site 1509)
Ürümqi, Xinjiang, China
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.